Recent Updates
Recently added Catalysts
LCTX Positive Sentiment

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lineage Cell Therapeutics announced it will report its third quarter 2026 financial results on November 12, 2026. The report will follow the close of U.S. financial markets. Additionally, management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lineage will report Q3 2026 results soon.
  • Management will provide a business update.
  • The event includes a conference call and webcast.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~18 mo
Low dilution risk
Lead asset
OPC1
Phase 1 · Spinal Cord Injury Cervical

Full Press Release Details

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2026 financial and operating results on November 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on November 12, 2026, at 4:30 p.m. Eastern Time/1:

Frequently Asked Questions

When will Lineage report its Q3 2026 results?

Lineage will report its Q3 2026 results on November 12, 2026.

What time is the conference call on November 12?

The conference call will be at 4:30 p.m. Eastern Time.

What will be included in the Q3 report?

The report will include financial and operating results.

Where can I access the webcast?

The webcast will be available during the conference call.

ShareAdd on Google
Tags: LCTX Lineage Cell Therapeutics Q3 2026 financial results business update
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$51M liquidity · $2M/mo burn
~18 mo
Low dilution risk
Lead asset
OPC1Phase 1
Spinal Cord Injury Cervical →